Innovative Medical Research Solutions
Advancing healthcare through cutting-edge development.
Innovative Medical Research Solutions
Advancing healthcare through cutting-edge development.
About Cytolysis Pharma
Innovative Research
At Cytolysis Pharma, we are dedicated to pioneering innovative research in the medical field. Our team focuses on developing groundbreaking therapies that aim to improve patient outcomes and advance healthcare.
PRADAB is a patented, cytolytic drug, developed for intratumoral administration, combined with aspiration of lysed tumor: a transformative therapeutic regimen for glioblastoma multiforme (GBM), the most aggressive primary brain tumor, as well as for all high-grade brain malignancies. Developed by a world-class team of neurosurgeons, clinical chemists, molecular biologists, and pharmacologists, PRADAB combines prazosin with L-2,4-diaminobutyric acid for selective tumor cells’ death by cytolysis, with neither local nor systemic side effects.
who we are
CV of PANOTOPOULOS CHRISTOS
1989: Medical Doctor - Medical Faculty of Athens University.
1989-1991: Army training and service as Medical Doctor in Hellenic Air Force.
1991-1997: Neurosurgery resident in “General National Hospital”, “KAT Hospital” and “Red Cross Hospital”, Athens, Greece.
1997: Title of Speciality in Neurosurgery - Prefecture of Athens.
1997-1998: Neurosurgeon in Hôpital Kremlin-Bicêtre, Université Paris ΧΙ.
1997-2000: Preclinical research concerning hypothalamic pathophysiology in the «Institut Européen des Sciences de Goût et des Comportements Alimentaires» (IESGCA), Dijon, France and in the Research Unit INSERM 518-U, Centre Nationale de Recherche Scientifique (CNRS), Grenoble, France.
1998: Ph.D. - Medical Faculty of Athens University.
1998 - 2000: Neurosurgeon and member of the clinical research team for Parkinson’s tremor and spasticity treatment by deep brain stimulation (DBS) in Hôpital Nord, Université Joseph Fourrier, Grenoble, France.
2000-2017: Preclinical and Clinical Research in the Neurosurgical and Neuropsychopharmacology Departments, Karolinska Institutet, Stockholm, Sweden and in the Neurosurgical, Anaesthesiology and Physiology Departments, Lund University, Lund, Sweden, concerning brain trauma metabolism and intratumoral chemotherapy for brain malignant tumors.
2001-2007: Visiting Consultant Neurosurgeon in Mediterraneo Hospital, Athens, Greece.
2002-2017: Foundation and administration of Jaymore Enterprises Ltd, exclusive distributor of preclinical and clinical extracellular biochemical monitoring’s products in Greece, Cyprus and India (produced by CMA Microdialysis AB and then by Mdialysis AB in Sweden - continued distribution by Inderes Ltd from 2018 onwards). Preclinical and clinical microdialysis research for brain trauma and high-grade gliomas.
2005-2015: Director of brain cancer research in ONNSA Research Foundation, Bangalore, India.
2007-2015: Visiting Senior Consultant Neurosurgeon in BGS Hospital and Director in BGS Institute of Neurosciences, Bangalore, India.
2007-2015: Visiting Senior Consultant Neurosurgeon and Director of Neurosurgical Research in Mediterraneo Hospital, Athens, Greece.
2011-2018: Foundation and administration of FEX Endotherapy Ltd, pioneering research related to the preclinical and clinical proof of the proprietary “fluid exchange” therapeutic concept and catheter system, aiming to its first application: a novel treatment for haemorrhagic stroke and intracranial abscess.
2012-2018: Foundation and Scientific Direction of IRRAS AB, Stockholm, Sweden, which produced the first fluid exchange catheter system, using only physiological solutions - no drugs - for evacuation of pathological intracranial fluid collections, the “IRRAflow®”. Thousands of haemorrhagic stroke and abscess patients treated in 22 countries so far, showed the clinical superiority of this therapeutic approach over existing treatments, as described in many publications and explained in https://irras.com/wp-content/uploads/2019/01/NNDr-Christos-Interview-on-IRRAflow-Final.pdf.
2015-today: Visiting Professor of Neurosurgery in BRAINS Hospital, Bangalore, India & Mediterraneo Hospital, Athens, Greece.
2016-today: Proprietary research in the Molecular Biology Department of BSRC A. FLEMMING, Vari, Greece and in the Clinical Chemistry Department of Uppsala University, Uppsala, Sweden, related to the development of “PRADAB” and “FLEPS”:
- PRADAB (PRAzosin + DiAminoButyric acid) is the first cancer chemotherapy drug developed exclusively for intratumoral administration - neither cytostatic nor cytotoxic but with cytolytic action on malignant cell’s cytoplasm
- FLEPS (FLuid Exchange Pharmacological System) is the first fluid exchange catheter system using drugs as well as physiological solutions, a totally improved evolution of Irraflow, designed for both intracranial and body therapeutic applications.
2018-today: Foundation and direction of INDependent RESearchers - INDERES LTD, an intellectual property company of an international multidisciplinary team (developing PRADAB, FLEPS and POLYLAVIS - a novel multifunctional surgical instrument, aiming to reduce significantly operational time, thus post operative complications, in all types of surgery).
2023-today: Visiting Professor, Neurosurgical Department, St John's Medical College Hospital and National Academy of Health Sciences (SJNAHS), Bangalore, India.
2025: Publication of a novel approach to cancer chemotherapy using PRADAB, elucidated by two brain cancer patients with remarkable clinical outcome and MRI proof of malignant tumor’s cytolytic liquefaction (https://www.dropbox.com/scl/fi/019corygnepoetnt0etn8/Panotopoulos_2025.pdf?rlkey=mdje63qtp1g3l6oxo0iw3rtrn&dl=0).